Uptake of Controlled Release Drug Delivery Technology Set to Increase?
News Dec 11, 2017 | Future Market Insights (FMI)
Oral Controlled Release Drug Delivery Technology Reports Increased Uptake, Observes Future Market Insights
The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages. Moreover, the uptake of controlled release drug delivery technology is anticipated to increase further in the near future with a large pool of drug manufacturers setting up their production unit across various regions, especially in Brazil, Costa Rica, Argentina, and Mexico.
Since the combination of several technologies assists in conquering the issues associated with poorly soluble candidates rapidly, the adoption of this technique is also increasing significantly. Being supported through increased sharing of technologies using various symposiums and conferences, where enterprises that share similar thought processes come together and plan eventual outcomes, which significantly helps in providing better pricing and swift time to market for the otherwise unfeasible products in the lesser period of time. An increased adoption of combination approaches is anticipated to propel the worldwide market for oral controlled release drug delivery technology in the years to come.
Over the next few years, the rising number of approvals of modified oral drugs by PMDA is likely to boost the revenue from oral controlled release drug delivery technology in Japan. In case of new approvals, a preference for capsules and tablets can be observed across the world, since formulation researchers find it easier to create formulations for therapeutic as well as clinical purposes.
Controlled Release Formulations – A common strategy to extend the product life cycle
Controlled Release is the most common strategy adopted by Pharma giants across the globe to extend the product life cycle. Modified or controlled release formulations of pre-approved drugs are enjoying extended market exclusivity. The introduction of proprietary prescribed medicines in controlled release forms will help drive revenue growth of the global market. Other release mechanisms include enteric release, osmotically active release, effervescent and sublingual release. OROS (Johnson & Johnson and Alza Corporation) and SODAS (Elan Technologies) are the most commercialised technologies in the oral controlled release drug delivery technology market.
This article has been republished from materials provided by Future Market Insights (FMI). Note: material may have been edited for length and content. For further information, please contact the cited source.
Research Report available here.
“Lymphoma Micro-reactor” Targets Chemo-Resistant LymphomaNews
Researchers have developed a “lymphoma micro-reactor” device that exposes human lymphomas to fluid flow similar to that in the lymphatics and parts of the lymph node.READ MORE
Targeting Telomerase: A Therapeutic Strategy for Difficult-to-Treat MelanomaNews
Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in Oncogene.READ MORE
Comments | 0 ADD COMMENT
Asia Pacific Congress on Probiotics, Prebiotics and Nutrition
Oct 15 - Oct 16, 2018